Cellectar Biosciences INC NEW (CLRB) is a publicly traded Healthcare sector company. As of May 21, 2026, CLRB trades at $3.09 with a market cap of $25.09M and a P/E ratio of -0.38. CLRB moved +3.43% today. Year to date, CLRB is -5.37%; over the trailing twelve months it is -59.97%. Its 52-week range spans $2.43 to $67.50. Analyst consensus is strong buy with an average price target of $10.33. Rallies surfaces CLRB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CLRB news today?
Cellectar Biosciences Secures $140M, Posts 61.8% MRR and 83.6% ORR: Cellectar Biosciences secured up to $140 million in financing to advance its Iopofosine I-131 Phase 3 study for relapsed/refractory Waldenström Macroglobulinemia and FDA accelerated approval filing. The Phase 2b CLOVER-WaM data showed a 61.8% major response rate, 83.6% overall response rate and 13.5-month progression-free survival after 12-month follow-up.
Cellectar Biosciences Secures $140M, Posts 61.8% MRR and 83.6% ORR: Cellectar Biosciences secured up to $140 million in financing to advance its Iopofosine I-131 Phase 3 study for relapsed/refractory Waldenström Macroglobulinemia and FDA accelerated approval filing. The Phase 2b CLOVER-WaM data showed a 61.8% major response rate, 83.6% overall response rate and 13.5-month progression-free survival after 12-month follow-up.
Does Rallies summarize CLRB news?
Yes. Rallies summarizes CLRB news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CLRB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CLRB. It does not provide personalized investment advice.
